Who Owns Smell
Four companies you have never heard of create most of the perfume in the world. This is what they are worth, how they built the moat, and what it means to be a house that buys from them.
The name on the bottle almost never made what is inside it. The perfume you wore today was, in all likelihood, composed inside one of four enormous, publicly traded companies, sold as a formula to the brand whose logo you paid for. The brand owns the story. These four own the smell.
This is a report about that arrangement, and it is a money story before it is anything else, because the money is public and the money is enormous. Givaudan, dsm-firmenich, International Flavors and Fragrances, and Symrise file audited accounts every quarter. Read them and a structure appears that most people who love perfume have never been shown: a mature oligopoly, with real revenues, real moats, and real power over what a perfume is allowed to become. We read it from a particular seat, a small independent house in Indonesia, which is to say from the position of a company that buys its raw materials from its own competitors' suppliers, and grows, in its own soil, some of what those giants resell to the world.
Fragrance creation is an oligopoly of four listed giants with combined sales above thirty billion dollars a year. They win not on secrecy but on scale, patents, and the safety apparatus they fund. A brand rents their work. An independent house can rent it too, which is the opening, and the trap.
- The maker is not the brand. Most fine fragrance is created by a handful of ingredient houses and licensed to the label on the bottle. The perfumer usually works for the supplier, not the marque.
- Four names dominate. Givaudan, dsm-firmenich, IFF and Symrise together booked well over thirty billion dollars in 2024 sales across flavour and fragrance, and their fragrance divisions alone run to roughly twelve to thirteen billion.
- It is a compound business, not a perfume business. The giants sell concentrate to brands the way a chip foundry sells silicon. The glamour bottle is a shop window for an industrial product sold by the tonne.
- Fine fragrance is the smallest part. The real volume is in the scent of detergent, shampoo, softener and soap. The perfume on the counter is a rounding error dressed as the main event.
- The moat is patents and scale. Captive molecules protected for twenty years, buying power in naturals, and research budgets in the hundreds of millions keep the club closed to newcomers.
- They also fund the rulebook. The same houses underwrite the science and the standards that decide which materials anyone may use, a governance moat we documented in a companion report.
- A small house is their customer. An independent buys from the same suppliers, can reach most of the palette, but cannot touch the protected molecules or the volume prices. The door is open and narrow.
- The ground is theirs, and ours. The naturals the giants resell are grown in places like Indonesia, which sells the base of world perfumery by the drum and buys the finished art back at a markup.
The four
The name on the bottle is a licence, not a workshop.
Begin with the fact that reorganises everything. When a fashion house or a celebrity launches a perfume, they very rarely make it. They write a brief, a paragraph of mood and ambition and a budget, and they send it to the fragrance houses, who compete to answer it. A perfumer, almost always an employee of one of those suppliers rather than of the brand, composes the formula. The winning house then manufactures the concentrate and sells it to the brand, which dilutes it, bottles it, and prints its own name on the front.
This is not a scandal and it is not hidden. It is simply the industrial structure of an art most people assume is artisanal. The consequence is that the creative and commercial power sits one layer below the names everyone knows. The brand owns the marketing and the margin. The house owns the molecule, the formula, and increasingly the patent. To ask who owns smell is to look past the logo to the four companies behind almost all of them.
You have worn the work of Givaudan, dsm-firmenich, IFF and Symrise your whole life, in your perfume, your shampoo, your detergent and your soap, and you have almost certainly never seen their names. That invisibility is not an accident. It is the business model.
Meet the companies that actually make the perfume.
Here they are, at 2024 scale, in their own audited figures. These are total group sales across both flavour and fragrance, because all four are twinned taste-and-scent businesses, with the fragrance and beauty divisions noted beside them. The currencies differ because the head offices do, in Switzerland, the Netherlands, the United States and Germany.
Givaudan. Swiss, the largest. Fragrance and Beauty alone was CHF 3,660m in 2024, with fine fragrance up 18.4 per cent.1
dsm-firmenich. Dutch-Swiss, born of a 2023 merger. Perfumery and Beauty was €3,964m, near a third of the group.2
IFF. American, New York. The Scent segment ran $2.44bn in 2024, up a comparable twelve per cent.3
Symrise. German, Holzminden. Scent and Care was €1,908m, up 8.9 per cent on the year.4
Drag from the fragrance division to the whole group
These are the fragrance and beauty divisions only, the part of each giant that concerns scent. Even trimmed to that slice, the four together clear roughly twelve billion dollars a year. Drag right to see the whole company each division sits inside.
The segment figures are not strictly comparable. Givaudan's Fragrance and Beauty and dsm-firmenich's Perfumery and Beauty both fold in cosmetic actives, Symrise's Scent and Care includes aroma molecules and cosmetic ingredients, and only IFF's Scent is close to pure fragrance. We use them because they are the audited lines the companies actually publish. The direction of the story does not depend on the second decimal.
A fifth tier sits just below, and it matters, because it is where an independent's supplier often really lives. Takasago of Japan, Robertet and Mane of France, and a long tail of smaller compounders make up the rest. Robertet and Mane in particular are the houses a naturals-led independent is most likely to buy from. But the top four set the prices, hold the patents, and employ most of the star perfumers, and it is their structure that defines the market everyone else operates inside.
The machine
A brand does not make a perfume. It runs a competition.
The mechanism is closer to advertising than to craft. A brand issues a brief to several fragrance houses at once. Each house puts its perfumers and its evaluation teams to work and submits trials, often many rounds of them, at its own cost. The brand tests them, on strips and on people, and picks a winner. The losing houses absorb the development expense as the price of being in the game. The winner is paid not for the creativity but for the concentrate, sold by the kilogram for as long as the perfume is on sale.
This is a razor-and-blades business turned inside out. The creative work is given away to win the account; the money is made on the recurring supply of the liquid. It rewards exactly the things a giant has and an independent does not: the capacity to lose dozens of pitches a year, a deep bench of salaried perfumers, industrial evaluation, and the balance sheet to fund all of it while waiting for the volume contracts that pay it back. The structure does not merely favour scale. It is built out of scale.
The perfumer works for the supplier, the supplier works for the brand, and the brand works for the shelf. The person who made your scent is three names below the one you paid.On the chain of authorship
The perfume on the counter is the smallest part of the business.
Here is the fact that reframes the whole industry. Fine fragrance, the bottles on the department store counter, is the glamorous minority of what these companies do. The volume, the tonnage, the ballast of the business, is functional scent: the smell engineered into laundry detergent, fabric softener, shampoo, shower gel, deodorant, dish soap and household cleaner. Givaudan reports its fragrance in exactly these buckets, and Consumer Products, the functional side, dwarfs Fine Fragrance even in a year when fine fragrance grew fastest.1
Givaudan's fine fragrance growth in 2024, the fastest-rising unit, and still the smaller one by volume.1
The finished perfume retail market in 2022, on a path toward roughly $73bn by 2030. The creation market beneath it is a different, smaller number, and the four own most of it.6
Roughly the share of the world's fragrance, by volume, that traces back to the seven largest suppliers. Concentration, not competition, is the resting state.7
The point is not that functional scent is unglamorous. It is that the economics of the whole industry are set by it. A house that perfumes a nation's laundry has buying power in naturals, research budgets, and pricing leverage that no fine-fragrance boutique can match, and it brings all of that to bear on the counter bottle too. When you smell a designer perfume, you are smelling the by-product of an industrial scent business, made by a company whose real customer is a detergent brand. The artistry is real. The engine underneath it is chemical manufacturing at national scale.
The moat
Why the club has stayed closed for a hundred years.
Oligopolies persist when the barriers to entry are real, and here they are unusually high and unusually specific. The first is the captive molecule. When a house invents a new aroma chemical, it patents it, and for roughly two decades no competitor may use it. These captives become the signature of a decade of perfumery, and only the house that owns one, and its paying clients, may build with it. The most famous of them defined the smell of an era while remaining, legally, the private property of a single company.
The second barrier is scale in raw materials. A house that buys naturals for the world's detergent has purchasing power a boutique cannot approach, which means it pays less for the same rose or patchouli and can absorb a failed harvest that would sink a small buyer. The third is research. The leading houses spend in the hundreds of millions each year on discovery, from new molecules to biotechnology to the digital tools now used to predict a scent before it is mixed. The fourth, quietest and most powerful, is the safety and regulatory apparatus, which we treat separately because it deserves its own chapter.
A newcomer would need, at once, a portfolio of patented molecules, buying power in dozens of naturals, a research budget in nine figures, a bench of trained perfumers, and a seat at the table where the rules are written. No amount of talent substitutes for any one of them. This is why the last century produced consolidation, not challengers.
The deepest moat is the one that looks like safety.
The materials any perfumer may legally use at scale are governed by the Standards of the International Fragrance Association, and the science behind those Standards is produced by the Research Institute for Fragrance Materials. Both are funded by the industry they regulate, and the largest funders are the same four to seven houses that dominate creation.7 We documented the mechanics of this arrangement in a companion report, and the conclusion bears repeating here in commercial terms.
When the body that decides which materials may be used is funded by the companies that also sell the replacements, the rulebook becomes a competitive instrument as much as a safety one. A restriction that removes a cheap natural and creates demand for a patented synthetic is, whatever its safety merit, also a transfer of value toward the houses that own the synthetic. This is not a claim that the science is false. It is an observation that the incentives are structural, and that the smaller and independent makers, who have no seat at that table, live under rules they did not help write and cannot afford to contest.
The full account of who writes the Standards, how the science is funded, and what the rules removed from the world's perfumes is set out in our report on the same subject. Read here for the money, read there for the mechanism. The two are the same story told from two sides.
A moat made of safety is the strongest kind, because to attack it you must appear to be attacking safety.On regulation as competitive advantage
From the floor
An independent house buys from its competitors' suppliers.
This is where the map stops being trivia and starts being strategy, because a small house lives inside this structure whether it understands it or not. When an independent brand composes its own perfumes, it buys its materials from the same oil houses and compounders that supply the giants, or from the specialist naturals firms a tier below. It can reach most of the classical palette. What it cannot reach are the captive molecules locked behind patents, and the prices that only tonnage unlocks. The independent pays retail for what the giant pays wholesale, and composes without the newest tools the giant invented.
The giant
Owns the molecule and the price. It creates captives, patents them, buys naturals by the tonne, funds the research and sits on the standards bodies. Its edge is structural and compounding. Its weakness is that it must serve a thousand briefs at once, converge on what tests well, and answer to a share price. It cannot easily be strange.
The independent
Owns the point of view. It cannot match the palette or the price, and it should not try. Its edge is that it answers to no brief but its own, can overdose a natural a committee would have cut, and can tell a true story of place and hand. Its weakness is that it rents most of its materials from the very companies it competes with.
You cannot out-scale the four, so do not try to compete where scale wins, on price, on breadth, on the newest captive. Compete where scale is a liability: on strangeness, on narrative, on the freedom to make one uncompromised thing for a small audience that the giants structurally cannot make.
The giants resell what our ground grows.
There is a closing turn in this that is particular to a house standing in Indonesia, and it is the sharpest fact in the report. The four giants are creators and compounders, but they are not, mostly, growers. The naturals at the base of their formulas come from the fields of the tropics and the Mediterranean, and a large share of the darkest, most structural of them come from Indonesian soil. The country supplies the great majority of the world's patchouli, along with vetiver, clove, nutmeg and benzoin, and it mostly ships them out raw, as oil in drums, to be composed elsewhere and sold back as finished art.
So the ownership question has a second floor. The giants own the molecule and the formula and the patent. But underneath the molecule is a material, and underneath the material is a farm, and the farm is here. A house rooted in the growing country is closer to the raw truth of the perfume than any company in Geneva or Holzminden, and that proximity is not sentimental. It is a strategic asset the four cannot buy, because it is not for sale. It is a place.
They own the formula. We grow the material the formula is made of. Ownership runs deeper than the patent, all the way down to the soil.HoM Haute
Where it goes
Four is not the floor. It is the current resting place of a long consolidation.
The number four is recent and unstable. It is the product of a wave of mergers that has been running for two decades and shows no sign of stopping. IFF absorbed the fragrance pioneer Frutarom in 2018 and then merged with DuPont's Nutrition and Biosciences arm in 2021, briefly making it the largest of all. Firmenich, for a century a proud private house, merged with the Dutch nutrition giant DSM in 2023 to create dsm-firmenich. Givaudan grew by a long series of acquisitions into the market leader. Each merger was justified by scale, by research, by the ability to serve global brands in one contract, which is to say by exactly the moat this report describes, made deeper.
The direction of travel is clear. Consolidation begets consolidation, because the barriers that keep newcomers out also make it rational for the incumbents to combine. A perfume industry that looks, from the counter, like a riot of competing brands is, one layer down, a small and shrinking number of suppliers. The logos multiply. The makers merge.
The same structure that built the moat is leaking at the edges.
Two forces run against the tide, and both are openings for a small house that reads them early. The first is biotechnology, which is lowering the cost of materials that used to require scale, putting fermented sandalwood, musks and ambrox within reach of buyers who could never have afforded the natural or the captive. The giants are leading this, but they cannot fully own it, and it hands a wider palette to everyone below them. The second is the counter-movement in taste itself, the growing hunger for the authentic, the local, the hand-made and the story-rich, precisely the register the four structurally cannot occupy.
So the instruction for an independent is not to rage against the oligopoly, which is a fixed feature of the landscape, but to position deliberately against it. Buy the palette they resell, yes. But build the one thing they cannot: a perfume with a point of view, a provenance that is true rather than sourced, and a reason to exist that a committee answering to a share price would have killed in the first round. The four own smell in the aggregate. They do not, and cannot, own meaning. That is the corner left for everyone else, and it is a good corner to be standing in.
How independent is your bottle?
Where these figures come from
Segment figures are the audited lines each company publishes and are not strictly comparable across houses, since each defines its fragrance division differently. Currency conversions in the interactive are approximate and for comparison only. Company figures are full year 2024; the finished-market projection and share figures are the latest available. The argument is built to survive revisions to the second decimal.